-
公开(公告)号：WO2019213526A1
公开(公告)日：2019-11-07
申请号：PCT/US2019/030606
申请日：2019-05-03
Applicant: AMGEN INC.
Inventor： WURZ, Ryan Paul , CEE, Victor, J. , AMEGADZIE, Albert , CHEN, Ning , LANMAN, Brian, Alan , BARTBERGER, Michael, D.
IPC: C07F9/6561 , A61K31/553 , A61K45/06
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
2.发明申请BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES 审中-公开与葡萄糖激素调节蛋白质相互作用以治疗糖尿病的苯二酚和苯并二氧化锌化合物
公开(公告)号：WO2012138776A1
公开(公告)日：2012-10-11
申请号：PCT/US2012/032192
申请日：2012-04-04
Applicant: AMGEN INC. , BARTBERGER, Michael, D. , CROGHAN, Michael, D. , FOTSCH, Christopher, H. , NORMAN, Mark, H. , PENNINGTON, Lewis, D. , REICHELT, Andreas , ST. JEAN, David, J., Jr. , TEGLEY, Christopher, M.
Inventor： BARTBERGER, Michael, D. , CROGHAN, Michael, D. , FOTSCH, Christopher, H. , NORMAN, Mark, H. , PENNINGTON, Lewis, D. , REICHELT, Andreas , ST. JEAN, David, J., Jr. , TEGLEY, Christopher, M.
IPC: C07D321/10 , C07D333/58 , C07D407/12 , C07D407/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04 , A61K31/357 , A61K31/381 , A61K31/422
CPC classification number: A61K31/506 , A61K31/155 , A61K31/357 , A61K31/381 , A61K31/422 , A61K31/427 , A61K31/429 , A61K31/4365 , A61K31/443 , A61K31/4436 , A61K31/4709 , A61K45/06 , C07D321/10 , C07D333/58 , C07D405/14 , C07D407/12 , C07D407/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04 , A61K2300/00
Abstract: The present invention relates to compounds of formula I or II, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
Abstract translation: 本发明涉及与葡萄糖激酶调节蛋白相互作用的式I或II化合物或其药学上可接受的盐。 此外，本发明还涉及治疗2型糖尿病的方法，以及使用该化合物或其药学上可接受的盐涉及葡萄糖激酶调节蛋白的其它疾病和/或病症，以及含有该化合物或其药学上可接受的盐的药物组合物 它们。
-
3.发明申请CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER 审中-公开CIS-MORPHOLINONE和其他化合物作为MDM2抑制剂治疗癌症
公开(公告)号：WO2014130470A1
公开(公告)日：2014-08-28
申请号：PCT/US2014/016971
申请日：2014-02-18
Applicant: AMGEN INC.
Inventor： BARTBERGER, Michael, D. , BECK, Hilary, Plake , DEGRAFFENREID, Michael, R. , FOX, Brian, M. , GONZALEZ LOPEZ DE TURISO, Felix , JULIAN, Lisa, D. , KAYSER, Frank , MEDINA, Julio, C. , OLSON, Steven, H. , REW, Yosup , ROVETO, Philip, M. , SUN, Daqing , YAN, Xuelei
IPC: C07D265/32 , C07D413/04 , C07D413/06 , C07D279/12 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61P35/00
CPC classification number: C07D265/32 , C07D279/12 , C07D413/04 , C07D413/06 , C07D487/04
Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
Abstract translation: 本发明提供式（I）的MDM2抑制剂化合物或其药学上可接受的盐，其中变量如上所定义，哪些化合物可用作治疗剂，特别是用于治疗癌症。 本发明还涉及含有MDM2抑制剂的药物组合物。
-
4.发明申请SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 审中-公开作为LLDP-HSD-1的抑制剂的替代的AZOLE AROMATIC HETEROCYCLES
公开(公告)号：WO2008011453A2
公开(公告)日：2008-01-24
申请号：PCT/US2007/073767
申请日：2007-07-18
Applicant: AMGEN INC. , BIOVITRUM AB , FOTSCH, Christopher, H. , BARTBERGER, Michael, D. , HARALDSSON, Martin , ST. JEAN, David , JOHANSSON, Lars , NILSSON, Marianne , SUTIN, Lori
Inventor： FOTSCH, Christopher, H. , BARTBERGER, Michael, D. , HARALDSSON, Martin , ST. JEAN, David , JOHANSSON, Lars , NILSSON, Marianne , SUTIN, Lori
CPC classification number: C07D403/06 , C07D413/06 , C07D413/12
Abstract: Compounds of formula I and IV are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:formula I and IV wherein the variables A-B, R, 1, r R> 2, m, and Q are described herein.
Abstract translation: 描述了式I和IV的化合物，具有治疗效用，特别是治疗糖尿病，肥胖症和相关病症和病症：式I和IV，其中变量AB，R，1，r R> 2，m和Q为 在此描述。
-
公开(公告)号：WO2005116002A3
公开(公告)日：2005-12-08
申请号：PCT/US2005/018081
申请日：2005-05-24
Applicant: AMGEN INC. , BIOVITRUM AB , HENRIKSSON, Martin , HOMAN, Evert , JOHANSSON, Lars , VALLGARDA, Jerk , WILLIAMS, Meredith , BERCOT, Eric , FOTSCH, Christopher, H. , LI, Aiwen , CAI, Guolin , HUNGATE, Randall, W. , YUAN, Chester, Chenguang , TEGLEY, Chirstopher , ST. JEAN, David , HAN, Nianhe , HUANG, Qi , LIU, Qingyian , BARTBERGER, Michael, D. , MONIZ, George, A. , FRIZZLE, Matthew, J.
Inventor： HENRIKSSON, Martin , HOMAN, Evert , JOHANSSON, Lars , VALLGARDA, Jerk , WILLIAMS, Meredith , BERCOT, Eric , FOTSCH, Christopher, H. , LI, Aiwen , CAI, Guolin , HUNGATE, Randall, W. , YUAN, Chester, Chenguang , TEGLEY, Chirstopher , ST. JEAN, David , HAN, Nianhe , HUANG, Qi , LIU, Qingyian , BARTBERGER, Michael, D. , MONIZ, George, A. , FRIZZLE, Matthew, J.
IPC: C07D277/54 , C07D263/48 , A61K31/42 , A61K31/426 , A61P3/04 , A61P3/00 , A61P3/06 , A61P3/10 , A61P19/10 , A61P31/12 , A61P29/00 , A61P25/28 , A61P25/24
Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): (I) (II), (III), or (IV), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.
-
Patent Agency Ranking6.发明公开CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER 有权CIS-MORPHOLINON UND ANDERE VERBINDUNGEN ALS MDM2-INHIBITOREN ZUR BEHANDLUNG VON KREBS
公开(公告)号：EP2958902A1
公开(公告)日：2015-12-30
申请号：EP14708410.7
申请日：2014-02-18
Applicant: Amgen Inc.
Inventor： BARTBERGER, Michael, D. , BECK, Hilary, Plake , DEGRAFFENREID, Michael, R. , FOX, Brian, M. , GONZALEZ LOPEZ DE TURISO, Felix , JULIAN, Lisa, D. , KAYSER, Frank , MEDINA, Julio, C. , OLSON, Steven, H. , REW, Yosup , ROVETO, Philip, M. , SUN, Daqing , YAN, Xuelei
IPC: C07D265/32 , C07D413/04 , C07D413/06 , C07D279/12 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61P35/00
CPC classification number: C07D265/32 , C07D279/12 , C07D413/04 , C07D413/06 , C07D487/04
Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
Abstract translation: 本发明提供式（I）的MDM2抑制剂化合物或其药学上可接受的盐，其中变量如上所定义，哪些化合物可用作治疗剂，特别是用于治疗癌症。 本发明还涉及含有MDM2抑制剂的药物组合物。
-
7.发明授权CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER 有权CIS-吗啡酮和其他化合物作为MDM2抑制剂用于治疗癌症
公开(公告)号：EP2958902B1
公开(公告)日：2017-11-15
申请号：EP14708410.7
申请日：2014-02-18
Applicant: Amgen Inc.
Inventor： BARTBERGER, Michael, D. , BECK, Hilary, Plake , DEGRAFFENREID, Michael, R. , FOX, Brian, M. , GONZALEZ LOPEZ DE TURISO, Felix , JULIAN, Lisa, D. , KAYSER, Frank , MEDINA, Julio, C. , OLSON, Steven, H. , REW, Yosup , ROVETO, Philip, M. , SUN, Daqing , YAN, Xuelei
IPC: C07D265/32 , C07D413/04 , C07D413/06 , C07D279/12 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61P35/00
CPC classification number: C07D265/32 , C07D279/12 , C07D413/04 , C07D413/06 , C07D487/04
-
公开(公告)号：EP3788053A1
公开(公告)日：2021-03-10
申请号：EP19725457.6
申请日：2019-05-03
Applicant: AMGEN INC.
Inventor： WURZ, Ryan Paul , CEE, Victor, J. , AMEGADZIE, Albert , CHEN, Ning , LANMAN, Brian, Alan , BARTBERGER, Michael, D.
IPC: C07F9/6561 , A61K31/553 , A61K45/06
-
9.发明公开BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES 审中-公开与蛋白质激酶调节蛋白相互作用BENZODIOXEPIN-和治疗糖尿病BENZODIOXINVERBINDUNGEN TO
公开(公告)号：EP2694491A1
公开(公告)日：2014-02-12
申请号：EP12713839.4
申请日：2012-04-04
Applicant: Amgen Inc.
Inventor： BARTBERGER, Michael, D. , CROGHAN, Michael, D. , FOTSCH, Christopher, H. , NORMAN, Mark, H. , PENNINGTON, Lewis, D. , REICHELT, Andreas , ST. JEAN, David, J., Jr. , TEGLEY, Christopher, M.
IPC: C07D321/10 , C07D333/58 , C07D407/12 , C07D407/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04 , A61K31/357 , A61K31/381 , A61K31/422
CPC classification number: A61K31/506 , A61K31/155 , A61K31/357 , A61K31/381 , A61K31/422 , A61K31/427 , A61K31/429 , A61K31/4365 , A61K31/443 , A61K31/4436 , A61K31/4709 , A61K45/06 , C07D321/10 , C07D333/58 , C07D405/14 , C07D407/12 , C07D407/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04 , A61K2300/00
Abstract: The present invention relates to compounds of formula I or II, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
-
10.发明公开
公开(公告)号：EP2051977A2
公开(公告)日：2009-04-29
申请号：EP07813049.9
申请日：2007-07-18
Applicant: Amgen Inc. , Biovitrum AB
Inventor： FOTSCH, Christopher, H. , BARTBERGER, Michael, D. , HARALDSSON, Martin , ST. JEAN, David , JOHANSSON, Lars , NILSSON, Marianne , SUTIN, Lori
IPC: C07D403/06
CPC classification number: C07D403/06 , C07D413/06 , C07D413/12
Abstract: Compounds of formula I and IV are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:formula I and IV wherein the variables A-B, R, 1, r R> 2, m, and Q are described herein.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.03 seconds)
